4.18

0.24% +0.010

After Hours: 4.08 -0.10 -2.39%

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Discussions Forecast Stock Split

Cardiff Oncology Inc stock is currently priced at $4.18, with a 24-hour trading volume of 343.17K. It has seen a +0.24% increased in the last 24 hours and a -28.55% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.22 pivot point. If it approaches the $4.01 support level, significant changes may occur.

Previous Close:

$4.17

Open:

$4.17

24h Volume:

343.17K

Market Cap:

$186.75M

Revenue:

$488.00K

Net Income/Loss:

$-41.44M

P/E Ratio:

-4.6444

EPS:

-0.9

Net Cash Flow:

$-31.47M

1W Performance:

-7.11%

1M Performance:

-28.55%

6M Performance:

+335.42%

1Y Performance:

+186.30%

1D Range:

$4.09

$4.38

52W Range:

$0.94

$6.42

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

858 952 7570

Address

11055 Flintkote Avenue, San Diego, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2024-05-02

Latest SEC Filings

CRDF's Discussions on Twitter

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

Cardiff Oncology Inc Stock (CRDF) Latest News

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

GlobeNewswire Inc.

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

GlobeNewswire Inc.

Cardiff Oncology Inc Stock (CRDF) Financials Data

Cardiff Oncology Inc (CRDF) Revenue 2024

CRDF reported a revenue (TTM) of $488.00 thousand for the quarter ending December 31, 2023, a +26.42% rise year-over-year.

Cardiff Oncology Inc (CRDF) Net Income 2024

CRDF net income (TTM) was -$41.44 million for the quarter ending December 31, 2023, a -7.07% decrease year-over-year.

Cardiff Oncology Inc (CRDF) Cash Flow 2024

CRDF recorded a free cash flow (TTM) of -$31.47 million for the quarter ending December 31, 2023, a +9.64% increase year-over-year.

Cardiff Oncology Inc (CRDF) Earnings per Share 2024

CRDF earnings per share (TTM) was -$0.93 for the quarter ending December 31, 2023, a -4.49% decline year-over-year.

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.